The commercial arm bridging foundational cancer research
with scalable, real-world healthcare impact.
The commercial arm bridging foundational cancer research with scalable, real-world healthcare impact.
CRMY Technologies Sdn Bhd (CTSB) is a wholly owned subsidiary of Cancer Research Malaysia (CRMY). We are the dedicated commercial entity driving the translation of scientific research into tangible healthcare solutions.
Our core function revolves around scaling up breakthrough innovations such as MeMoSA®, Genetix, and the Cancer Vaccine program. We take pride in managing intellectual property, orchestrating licensing agreements, and providing the venture-building services required to take research outcomes from the laboratory to the patient.
A synergistic operational model designed to sustain, fund,
and accelerate cancer research in Malaysia.
A synergistic operational model designed to sustain, fund, and accelerate cancer research in Malaysia.
A private charitable research entity deeply focused on foundational cancer research, validation studies, and baseline scientific services. CRMY generates the intellectual property and biological discoveries that shape the future of oncology.
Fully owned by CRMY, functioning as the operational entity to generate revenue through commercial activities. CTSB takes the discoveries from CRMY and implements go-to-scale commercial models.
Expert management of intellectual property and patent portfolios.
Driving go-to-market strategies for products like MeMoSA® and Genetix.
Commercialising CRMY’s lab services for clinical integration to external clients.
CRMY holds 100% shareholding in CTSB. As such, no external shareholders exist at this stage, ensuring complete alignment with our foundational vision.
All proceeds derived from CTSB’s activities—including licensing income, joint ventures, and clinical service revenues—contribute directly to CRMY’s broader mission. Every commercial success is channelled back as donations to fund the next wave of cancer research.
We are actively seeking institutional partners,
clinical networks, and collaborators to expand the reach
of our innovative platforms.
We are actively seeking institutional partners, clinical networks, and collaborators to expand the reach of our innovative platforms.
